• OPEN AN ACCOUNT
Indian Indices
Sensex
83,580.40 266.47
( 0.32%)
Global Indices
Nasdaq
50,145.69 1,215.96
(2.49%)
Dow Jones
6,954.50 135.10
(1.98%)
Hang Seng
54,176.23 358.19
(0.67%)
Nikkei 225
10,359.93 50.71
(0.49%)
Forex
USD-INR
90.32 -0.07
(-0.08%)
EUR-INR
106.52 -0.28
(-0.26%)
GBP-INR
122.68 -1.05
(-0.85%)
JPY-INR
0.58 0.00
(-0.33%)

EQUITY - MARKET SCREENER

Tata Consumer Products Ltd
Industry :  Tea
BSE Code
ISIN Demat
Book Value()
500800
INE192A01025
174.2606593
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TATACONSUM
75.35
114673.54
EPS(TTM)
Face Value()
Div & Yield %
15.38
1
0.71
 

Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03
Jan 01,2026
AVT03 is a proposed biosimilar to Amgen’s Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company’s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.